<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002601</url>
  </required_header>
  <id_info>
    <org_study_id>94072</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-IRB-94072</secondary_id>
    <secondary_id>NCI-V94-0545</secondary_id>
    <secondary_id>CDR0000063845</secondary_id>
    <nct_id>NCT00002601</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma</brief_title>
  <official_title>High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug and combining chemotherapy with
      peripheral stem cell transplantation may allow the doctor to give higher doses of
      chemotherapy drugs and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy and
      peripheral stem cell transplantation in treating patients who have advanced or recurrent
      sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility of sequential high-dose chemotherapy with ifosfamide
      and doxorubicin followed by melphalan and cisplatin, each followed by autologous peripheral
      blood stem cell support, in patients with high-risk or advanced sarcomas. II. Determine the
      toxic effects of this regimen in these patients. III. Determine response rate and
      disease-free and overall survival in these patients treated with this regimen.

      OUTLINE: Beginning at least 4 weeks prior to the start of chemotherapy, patients receive
      filgrastim (G-CSF) subcutaneously daily until the completion of peripheral blood stem cell
      (PBSC) harvesting. Beginning 5 days after the start of G-CSF, PBSCs are collected over
      several days. Patients who do not mobilize sufficient cells undergo bone marrow harvest.
      Regimen A: Patients receive high-dose ifosfamide IV and doxorubicin IV continuously over 96
      hours on days -8 to -4. 12.5% of PBSCs or bone marrow are reinfused on day -2 and 37.5% are
      reinfused on day 0. Patients receive G-CSF IV beginning on day 0 and continuing until blood
      counts recover. Regimen B: Beginning at least 4 weeks after day 1 of Regimen A, patients
      receive high-dose melphalan IV followed immediately by cisplatin IV on days -11 and -4.
      Patients receive G-CSF IV on days -10 to -6. 12.5% of PBSCs or bone marrow are reinfused on
      day -3 and the remaining 37.5% are reinfused on day 0. Patients receive G-CSF IV beginning on
      day 0 and continuing until blood counts recover. Patients are followed monthly for 1 year,
      every 3 months for 1 year, and then as needed for 3 years.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1994</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 Bilirubin</measure>
    <time_frame>2 years after completion of treatment</time_frame>
    <description>Criteria for early termination of this feasibility study: &gt; 2 patients experience grade 4 or 5 hematologic toxicity or more that 3 patients experience grade 3 hematologic toxicity; &gt; 2 patients experience grade 3 hepatic or gastrointestinal toxicity or &gt; 3 patients are unable to receive the second cycle of treatment; &gt; 2 patients experience grade 5 toxicity related to treatment regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities Counts</measure>
    <time_frame>2 months after completion of second cycle of treatment.</time_frame>
    <description>Number of patients with grade 3 and 4 toxicities observed during cycles 1 &amp; 2 using the Common Toxicity Criteria Version for Chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year Progression-free Survival</measure>
    <time_frame>Until disease progression, up to 5 Years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 25% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Overall Survival</measure>
    <time_frame>Until death from any cause, up to 5 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>5 ug/kg daily following stem cell reinfusion</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2</description>
    <arm_group_label>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed sarcomas in the following categories:
        Soft tissue sarcoma (STS) High-grade STS of the extremities Primary extending to fascia or
        locally recurrent At least 10 cm in greatest dimension or multifocal on surgical pathology
        Primary site controlled by surgery and/or radiotherapy High-grade truncal or head and neck
        sarcoma At least 10 cm in greatest dimension or any size with no surgical options for clear
        margins Primary site controlled by surgery and/or radiotherapy Locally recurrent disease in
        CR or PR after surgery, chemotherapy, or radiotherapy Metastatic STS in CR or PR after
        surgery, chemotherapy, or radiotherapy Osteosarcoma (OS) Extremity OS after neoadjuvant
        chemotherapy and surgical resection provided: Less than 50% necrosis in the surgical
        specimen LDH or alkaline phosphatase greater than 2 times normal at presentation Axial OS
        in CR or PR after chemotherapy and/or surgery Primary or recurrent metastatic OS in CR or
        PR after chemotherapy, surgery, and/or radiotherapy Ewing's sarcoma or primitive
        neuroectodermal tumor Primary site in CR or PR after chemotherapy, radiotherapy, or surgery
        Rib, pelvic, or axial skeleton primary Bulky tumor (at least 10 cm in greatest diameter)
        Primary or recurrent metastatic disease in CR or PR after surgery, chemotherapy, or
        radiotherapy Rhabdomyosarcoma Gross residual disease after primary treatment with surgery,
        chemotherapy, and radiotherapy Primary group IV or recurrent metastatic disease in CR or PR
        after chemotherapy and radiotherapy with or without surgery No brain metastasis No
        histologically confirmed bone marrow metastasis Prior metastases allowed with clearing of
        bone marrow at entry No contraindication to collection of mobilized stem cells or, if
        needed, autologous bone marrow

        PATIENT CHARACTERISTICS: Age: 10 to 55 Performance status: Karnofsky 80-100% Hematopoietic:
        Absolute neutrophil count greater than 2,000/mm3 Platelet count greater than 150,000/mm3
        Hemoglobin greater than 10 g/dL Hepatic: See Disease Characteristics Bilirubin less than
        1.5 mg/dL AST and ALT less than 3 times normal Hepatitis B surface antigen negative
        Negative hepatitis C antigen test required in patients with hepatitis C antibody Renal:
        Creatinine less than 1.4 mg/dL Creatinine clearance greater than 75 mL/min Cardiovascular:
        LVEF at least 55% by MUGA or echocardiogram No history of significant cardiac disease
        Pulmonary: FEV1 greater than 2 liters PaO2 greater than 70 mm Hg on room air PaCO2 less
        than 42 mm Hg on room air DLCO greater than 60% predicted Other: No hearing loss of greater
        than 40 decibels HIV negative No organic or psychiatric CNS dysfunction that would preclude
        study No other medical or psychosocial problems that would place patient at unacceptable
        risk No history of other malignancy except nonmelanoma skin cancer or carcinoma in situ of
        the cervix Not pregnant Negative pregnancy test Fertile patients must use effective
        contraception

        PRIOR CONCURRENT THERAPY: More than 2 weeks since treatment to control primary or recurrent
        tumor Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No more
        than 2 prior chemotherapy regimens (including adjuvant therapy) Prior cumulative cisplatin
        dose less than 400 mg/m2 Prior cumulative doxorubicin dose less than 240 mg/m2 Endocrine
        therapy: Not specified Radiotherapy: See Disease Characteristics No prior radiotherapy to
        more than 20% of the bone marrow-containing axial skeleton No prior radiotherapy to the
        left chest wall Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Somlo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center and Beckman Research Institute, City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2004</study_first_posted>
  <results_first_submitted>November 21, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
          <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
          <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="21" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 Bilirubin</title>
        <description>Criteria for early termination of this feasibility study: &gt; 2 patients experience grade 4 or 5 hematologic toxicity or more that 3 patients experience grade 3 hematologic toxicity; &gt; 2 patients experience grade 3 hepatic or gastrointestinal toxicity or &gt; 3 patients are unable to receive the second cycle of treatment; &gt; 2 patients experience grade 5 toxicity related to treatment regimen.</description>
        <time_frame>2 years after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
            <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 Bilirubin</title>
          <description>Criteria for early termination of this feasibility study: &gt; 2 patients experience grade 4 or 5 hematologic toxicity or more that 3 patients experience grade 3 hematologic toxicity; &gt; 2 patients experience grade 3 hepatic or gastrointestinal toxicity or &gt; 3 patients are unable to receive the second cycle of treatment; &gt; 2 patients experience grade 5 toxicity related to treatment regimen.</description>
          <units>participants with Grade 3 Bilirubin</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Toxicities Counts</title>
        <description>Number of patients with grade 3 and 4 toxicities observed during cycles 1 &amp; 2 using the Common Toxicity Criteria Version for Chemotherapy.</description>
        <time_frame>2 months after completion of second cycle of treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycle 1</title>
            <description>Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.</description>
          </group>
          <group group_id="O2">
            <title>Cycle 2</title>
            <description>Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicities Counts</title>
          <description>Number of patients with grade 3 and 4 toxicities observed during cycles 1 &amp; 2 using the Common Toxicity Criteria Version for Chemotherapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bacteremia/sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary function impairment (FEV1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary infiltrates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated PTT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Progression-free Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 25% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions.</description>
        <time_frame>Until disease progression, up to 5 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
            <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Progression-free Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 25% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Overall Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.</description>
        <time_frame>Until death from any cause, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
            <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Overall Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="14" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected over a period of 45 months</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT</title>
          <description>Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COH</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dysrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>COH</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical Coagulation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dysrhythmias</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pericardial</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>EF/CHF</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Ear disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hearing</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vision</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Vomiting</sub_title>
                <counts group_id="E1" events="22" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical (Physical Exam)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Other Misc</sub_title>
                <counts group_id="E1" events="31" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever (no infection)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AGC</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Prothrombin Time</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SGOT/SGT</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>WBC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight (Food Intake)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperglycemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypocalcemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypomagnesemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cortical/State of Consciousness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Motor Activity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral Nervous System Sensory</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Taste alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ideation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mood</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hiccough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Extensive Skin Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Local Skin Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>(626)256-4673 ext 65265</phone>
      <email>pfrankel@och.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

